The South Korea Migraine Drug market size stood at around USD 19.6 million in 2019 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.
Migraine is a complex neurological condition, characterized by frequent headaches that can last from 4 to 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.
The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. According to a study in Journal of Clinical Neurology, the 1-year migraine prevalence rates in Korea in 2018 surveys was 5.2%.
Rising incidence of migraine, increase in awareness about migraine and its treatment and growth in R&D expenses are major drivers for this market.
Migraine pain is commonly prevalent in women as compared to men. This is attributed to the changes in oestrogen levels in females, especially during menstruation. Moreover, hormonal medications, such as oral contraceptives and hormone replacement therapy may further worsen migraine in women. Therefore, increase in the female population is anticipated to propel the growth of migraine drugs market. However, lack of proper diagnosis and undiagnosed cases, adverse effects of drugs, increased preference for alternative therapies, and generic penetration are the few factors hampering the migraine drugs market.